Jyong Biotech Showcases Botreso® After Four Phase III Trials, Accelerates NDA Prep
MENS•Jyong Biotech presented its botanical drug candidate Botreso® at BIO 2026, highlighting completion of four Phase III trials in the US and Taiwan for BPH and LUTS. The company is accelerating NDA preparations and engaging potential partners for regional licensing in the US, Europe and Asia to accelerate commercialization.
1. BIO 2026 Exhibition
Jyong Biotech exhibited its botanical drug portfolio at the BIO International Convention in San Diego from June 22 to June 25, marking over a decade of uninterrupted participation and facilitating discussions with global pharmaceutical companies, investors and industry partners.
2. Botreso® Phase III Trials
The company highlighted Botreso® (API-1), its new botanical drug candidate for benign prostatic hyperplasia and lower urinary tract symptoms, which has completed four Phase III clinical trials across the US and Taiwan demonstrating safety, tolerability and clinical efficacy.
3. NDA and Licensing Strategy
Faced with a projected 35–40% increase in BPH patients by 2035, Jyong Biotech is accelerating New Drug Application preparations and actively pursuing regional licensing agreements in the US, Europe and Asia to expedite global commercialization.
